High refractive index, high Abbe compositions
US-12071497-B2 · Aug 27, 2024 · US
Hydrogel contact lens for sustained drug release and drug release method using hydrogel contact lens for sustained drug release
US8940318B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-8940318-B2 |
| Application number | US-201013202547-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jan 15, 2010 |
| Priority date | Feb 20, 2009 |
| Publication date | Jan 27, 2015 |
| Grant date | Jan 27, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Disclosed is a sustainedly drug-releasing hydrogel contact lens which can sustainedly release an anionic medicament such as an allergy-treating agent in a mildly irritating and effective manner while achieving vision correction. Specifically disclosed is a hydrogel comprising ionic monomers composed of at least a cationic monomer and an anionic monomer, wherein the component ratio of the ionic monomers is 5 to 20 mol % inclusive relative to the total amount of monomers that constitute the gel, and the content of the anionic monomer is 15 to 25 mol % inclusive relative to the content of the cationic monomer.
First claim
Opening claim text (preview).
The invention claimed is: 1. A daily disposable hydrogel contact lens for sustained drug release of sustainedly releasing a dose of an anionic drug, wherein the amount of initial release in a time period of about 4 hours after the start of wearing the hydrogel contact lens is not more than 50% of the dose of the anionic drug contained in the hydrogel contact lens, and not less than 80% of the dose of the anionic drug contained in the hydrogel contact lens is released at least in 14…
Assignees
Inventors
Classifications
- G02B1/043Primary
Physics · mapped topic
Human Necessities · mapped topic
Human Necessities · mapped topic
Physics · mapped topic
Human Necessities · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US8940318B2 cover?
- Disclosed is a sustainedly drug-releasing hydrogel contact lens which can sustainedly release an anionic medicament such as an allergy-treating agent in a mildly irritating and effective manner while achieving vision correction. Specifically disclosed is a hydrogel comprising ionic monomers composed of at least a cationic monomer and an anionic monomer, wherein the component ratio of the ionic …
- Who is the assignee on this patent?
- Sato Takao, Matsunaga Toru, Ichinokawa Aya, and 3 more
- What technology area does this patent fall under?
- Primary CPC classification G02B1/043. Mapped technology areas include Physics.
- When was this patent published?
- Publication date Tue Jan 27 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).